Tabula Rasa Healthcare (NASDAQ:TRHC) initiated with Buy rating and $85 (31% upside) price target at Benchmark.Molina Healthcare (NYSE:MOH) upgraded to Overweight with a $142 (20%...
By Tamara Mathias and Ankur Banerjee (Reuters) - Eli Lilly (N:LLY) said on Monday it will buy Loxo Oncology Inc (O:LOXO) for $8 billion, an expensive bet on a pipeline of cancer...
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Consumer Services, Oil & Gas and Telecoms sectors led shares higher. At the close in NYSE, the...
Market watchers still quibble over whether the equity market entered bear market territory or underwent a correction in year-end 2018. But there is little debate over the fate of...
Eli Lilly & Company (NYSE:LLY) reported fourth-quarter 2018 adjusted earnings per share of $1.33, which missed the Zacks Consensus Estimate of $1.36 and matched the lower...
Investors in Loxo Oncology, Inc. (NASDAQ:LOXO) need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 15, 2019 $130.00 Put...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Neutral||Buy||Buy|
|Technical Indicators||Sell||Sell||Neutral||Strong Buy||Strong Buy|
|Summary||Strong Sell||Strong Sell||Neutral||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Up||1M||Current|
|Doji Star Bearish||1M||Current|
|Bullish Engulfing||1M||1||Jan 19|
|Advance Block Bearish||1M||11||Mar 18|
|Three Black Crows||1W||12||Nov 18, 2018|
Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity.Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.